Stock in Focus: Mirum Pharmaceuticals, Inc. (MIRM)

Company Profile:

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company’s lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Recent News:

On December 13, 2022, the company announced that the European Commission has granted marketing authorization for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older.

The company reported that Net product sales of LIVMARLI for the quarter ended September 30, 2022 were $18.8 million, compared to none for the quarter ended September 30, 2021. It raises 2022 full year net product sales guidance estimate for LIVMARLI to $70 million.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects:

Price to Book Value – P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.

@@@@@

Price to Earnings – PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).

@@@@@

Discounted cash flow – DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.

@@@@@

Return on Assets – ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.

@@@@@

Return on Equity – ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.

@@@@@

Debt to Equity – evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.

@@@@@

Conclusion:

MIRM receives outperform rating in price to book value, discounted cash flow and debt to equity. Technical indicators signal the bullish signs, as there is a bullish crossover in the MACD and Stochastic oscillator. The RSI(14) stands at 47.6 with positive bias. We rate Mirum Pharmaceuticals, Inc. (MIRM) a STRONG BUY.